Evidence map›Paper›PMID 34107233›Full record

ArticlePathogens and global health2021

A conceptual approach to the rationale for SARS-CoV-2 vaccine allocation prioritisation.

Malte Kohns Vasconcelos, Chantal Marazia, Markela Koniordou, Heiner Fangerau, Ingo Drexler, Anthony Afum-Adjei Awuah

Abstract read
In one paragraph

Article in Pathogens and global health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Malte Kohns VasconcelosInstitute for Medical Microbiology and Hospital Hygiene, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.ORCID 0000-0002-6207-9442
Chantal MaraziaDepartment of the History, Philosophy and Ethics of Medicine, Centre for Health and Society, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Markela KoniordouCenter for Clinical Epidemiology and Outcomes Research (CLEO), Athens, Greece.
Heiner FangerauDepartment of the History, Philosophy and Ethics of Medicine, Centre for Health and Society, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.ORCID 0000-0001-9065-3395
Ingo DrexlerInstitute for Virology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Anthony Afum-Adjei AwuahKumasi Centre for Collaborative Research in Tropical Medicine (KCCR), Kumasi, Ghana.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently vaccines protecting from COVID-19 are a scarce resource. Prioritising vaccination for certain groups of society is placed in a context of uncertainty due to changing evidence on the available vaccines and changing infection dynamics. To meet accepted ethical standards of procedural justice and individual autonomy, vaccine allocation strategies need to state reasons for prioritisation explicitly while at the same time communicating the expected risks and benefits of vaccination at different times and with different vaccines transparently. In this article, we provide a concept summarising epidemiological considerations underlying current vaccine prioritisation strategies in an accessible way. We define six priority groups (vulnerable individuals, persons in close contact with the vulnerable, key workers with direct work-related contact with the public, key workers without direct work-related contact to the public, dependents of key workers and members of groups with high interpersonal contact rates) and state vaccine priorities for them. Additionally, prioritisation may follow non-epidemiological considerations including the aim to increase intra-societal justice and reducing inequality. While national prioritisation plans integrate many of these concepts, the international community has so far failed to guarantee equitable or procedurally just access to vaccines across settings with different levels of wealth.

Indexed as

COVID-19VaccinesCOVID-19 VaccinesHumansSARS-CoV-2VaccinationCOVID-19 VaccinesVaccinesaccountability for reasonablenessCOVID-19vaccine confidence

Identifiers

PMID34107233
PMCPMC8547848

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.